Tumor response evaluation in oncology: current update
- PMID: 20657213
- DOI: 10.1097/RCT.0b013e3181db2670
Tumor response evaluation in oncology: current update
Abstract
Quantification of tumor burden and assessment of changes in tumor size after chemotherapy are commonly performed to evaluate treatment response in oncology trials. Validation and adoption of different criteria have been attempted in the past to achieve uniformity in scanning techniques and measurement metrics so that comparison of different oncological trials is feasible. Response assessment of solid tumors is usually consisted of either bidimensional (World Health Organization criteria) or unidimensional (Response Evaluation Criteria in Solid Tumors [RECIST] guidelines) measurement of tumors before and after chemotherapy. RECIST 1.1 criteria have been recently published. In this article, we try to provide a comprehensive review of the tumor response evaluation guidelines that were recently updated in attempts to overcome limitations of the previous criteria as well as incorporate recent advances in imaging techniques.
Similar articles
-
[New guidelines to evaluate the response to treatment "RECIST"].Gan To Kagaku Ryoho. 2000 Dec;27(14):2179-84. Gan To Kagaku Ryoho. 2000. PMID: 11142160 Review. Japanese.
-
Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology.Top Magn Reson Imaging. 2007 Jun;18(3):193-202. doi: 10.1097/RMR.0b013e318093e6bo. Top Magn Reson Imaging. 2007. PMID: 17762383 Review.
-
Selection of response criteria for clinical trials of sarcoma treatment.Oncologist. 2008;13 Suppl 2:32-40. doi: 10.1634/theoncologist.13-S2-32. Oncologist. 2008. PMID: 18434637 Review.
-
Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?Cancer. 2009 Feb 1;115(3):616-23. doi: 10.1002/cncr.24050. Cancer. 2009. PMID: 19117042
-
[New guidelines to evaluate the response to treatment in solid tumors].Bull Cancer. 2000 Dec;87(12):881-6. Bull Cancer. 2000. PMID: 11174117 French.
Cited by
-
Agreement Between the European Organization for Research and Treatment of Cancer and Positron Emission Tomography Response Criteria in Solid Tumors in Evaluating Treatment Response in Solid Malignant Tumors.Cureus. 2019 Aug 18;11(8):e5422. doi: 10.7759/cureus.5422. Cureus. 2019. PMID: 31632874 Free PMC article.
-
Intra- and inter-observer variability in measurement of target lesions: implication on response evaluation according to RECIST 1.1.Radiol Oncol. 2012 Mar;46(1):8-18. doi: 10.2478/v10019-012-0009-z. Epub 2012 Jan 2. Radiol Oncol. 2012. PMID: 22933974 Free PMC article.
-
GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker.Clinics (Sao Paulo). 2011;66(6):965-72. doi: 10.1590/s1807-59322011000600008. Clinics (Sao Paulo). 2011. PMID: 21808860 Free PMC article.
-
Proton and carbon ion radiotherapy in skull base chordomas: a prospective study based on a dual particle and a patient-customized treatment strategy.Neuro Oncol. 2020 Sep 29;22(9):1348-1358. doi: 10.1093/neuonc/noaa067. Neuro Oncol. 2020. PMID: 32193546 Free PMC article.
-
Serum Protein Pattern Could Predict the Therapeutic Effect of First-Line Pemetrexed/Cisplatin Chemotherapy in Patients With Lung Adenocarcinoma.World J Oncol. 2015 Feb;6(1):292-296. doi: 10.14740/wjon901w. Epub 2015 Feb 14. World J Oncol. 2015. PMID: 29147418 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous